234 related articles for article (PubMed ID: 16914642)
1. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
[TBL] [Abstract][Full Text] [Related]
2. Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation.
Meng LH; Ding J
Acta Pharmacol Sin; 2007 Sep; 28(9):1460-5. PubMed ID: 17723179
[TBL] [Abstract][Full Text] [Related]
3. The QTK loop is essential for the communication between the N-terminal atpase domain and the central cleavage--ligation region in human topoisomerase IIalpha.
Bendsen S; Oestergaard VH; Skouboe C; Brinch M; Knudsen BR; Andersen AH
Biochemistry; 2009 Jul; 48(27):6508-15. PubMed ID: 19485418
[TBL] [Abstract][Full Text] [Related]
4. A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
Huang H; Chen Q; Ku X; Meng L; Lin L; Wang X; Zhu C; Wang Y; Chen Z; Li M; Jiang H; Chen K; Ding J; Liu H
J Med Chem; 2010 Apr; 53(8):3048-64. PubMed ID: 20353152
[TBL] [Abstract][Full Text] [Related]
5. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
Liang H; Wu X; Yalowich JC; Hasinoff BB
Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
[TBL] [Abstract][Full Text] [Related]
6. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.
Jiménez-Alonso S; Orellana HC; Estévez-Braun A; Ravelo AG; Pérez-Sacau E; Machín F
J Med Chem; 2008 Nov; 51(21):6761-72. PubMed ID: 18816045
[TBL] [Abstract][Full Text] [Related]
8. The ATP-operated clamp of human DNA topoisomerase IIalpha: hyperstimulation of ATPase by "piggy-back" binding.
Campbell S; Maxwell A
J Mol Biol; 2002 Jul; 320(2):171-88. PubMed ID: 12079377
[TBL] [Abstract][Full Text] [Related]
9. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
Jensen LH; Thougaard AV; Grauslund M; Søkilde B; Carstensen EV; Dvinge HK; Scudiero DA; Jensen PB; Shoemaker RH; Sehested M
Cancer Res; 2005 Aug; 65(16):7470-7. PubMed ID: 16103101
[TBL] [Abstract][Full Text] [Related]
10. Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II.
Sorensen TK; Grauslund M; Jensen PB; Sehested M; Jensen LH
Biochem Biophys Res Commun; 2005 Sep; 334(3):853-60. PubMed ID: 16053917
[TBL] [Abstract][Full Text] [Related]
11. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIalpha and beta--distinct mode of action of two derivatives.
Sai Krishna AD; Panda G; Kondapi AK
Arch Biochem Biophys; 2005 Jun; 438(2):206-16. PubMed ID: 15907782
[TBL] [Abstract][Full Text] [Related]
13. Self-association and DNA binding properties of the human topoisomerase IIA alpha2HTH module.
Morant-Lhomel A; René B; Zargarian L; Troalen F; Mauffret O; Fermandjian S
Biochimie; 2006; 88(3-4):253-63. PubMed ID: 16213649
[TBL] [Abstract][Full Text] [Related]
14. DNA topoisomerase II as the primary cellular target for salvicine in Saccharomyces cerevisiae.
Meng LH; He XX; Zhang JS; Ding J
Acta Pharmacol Sin; 2001 Aug; 22(8):741-6. PubMed ID: 11749849
[TBL] [Abstract][Full Text] [Related]
15. Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects.
Hasinoff BB; Wu X; Yalowich JC; Goodfellow V; Laufer RS; Adedayo O; Dmitrienko GI
Anticancer Drugs; 2006 Aug; 17(7):825-37. PubMed ID: 16926632
[TBL] [Abstract][Full Text] [Related]
16. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
Zhou Z; Guan H; Kleinerman ES
Mol Cancer Res; 2005 May; 3(5):271-5. PubMed ID: 15886298
[TBL] [Abstract][Full Text] [Related]
17. Reactive oxygen species elicit apoptosis by concurrently disrupting topoisomerase II and DNA-dependent protein kinase.
Lu HR; Zhu H; Huang M; Chen Y; Cai YJ; Miao ZH; Zhang JS; Ding J
Mol Pharmacol; 2005 Oct; 68(4):983-94. PubMed ID: 16024664
[TBL] [Abstract][Full Text] [Related]
18. Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effects by trapping enzyme-DNA cleavage complexes.
Meng LH; Zhang JS; Ding J
Biochem Pharmacol; 2001 Sep; 62(6):733-41. PubMed ID: 11551518
[TBL] [Abstract][Full Text] [Related]
19. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.
Mao Y; Yu C; Hsieh TS; Nitiss JL; Liu AA; Wang H; Liu LF
Biochemistry; 1999 Aug; 38(33):10793-800. PubMed ID: 10451375
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U
Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
